Literature DB >> 4067847

Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin.

G S Duthu.   

Abstract

Knowledge of the disposition of macrolides in a single animal species has been insufficient for the prediction of the pharmacokinetics of macrolides in humans. To better understand the species differences in the pharmacokinetics of macrolide antibiotics, the disposition of erythromycin, oleandomycin, and tylosin in several mammalian species was examined. Generally, the serum concentration versus time profiles of these drugs after intravenous administration were described by two-compartment kinetic models and were similar within each species. These drugs were rapidly cleared, resulting in terminal half-lives of less than 2 h. Comparison of their pharmacokinetics showed greater variation in antibiotic disposition among animal species than noted for the differences within a species. When the pharmacokinetic data was fitted to an allometric model, the logarithms of volume of distribution, clearance, and half-life were linearly related to the logarithms of body weight. From these relationships, the human pharmacokinetics of erythromycin and oleandomycin were extrapolated and found to approximate observed human pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4067847     DOI: 10.1002/jps.2600740907

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Pharmacokinetics of oleandomycin in dogs after intravenous or oral administration alone and after pretreatment with metamizole or dexamethasone.

Authors:  A Milanova; L Lashev
Journal:  Vet Res Commun       Date:  2002-01       Impact factor: 2.459

2.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

Review 3.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 4.  Discovery and development of new antimicrobial agents.

Authors:  T D Gootz
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 5.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

6.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

7.  Fractal volume of drug distribution: it scales proportionally to body mass.

Authors:  V Karalis; L Claret; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

8.  The Chondroprotective Role of Erythromycin in a Murine Joint Destruction Model.

Authors:  Tomoya Uchimura; Andrea T Foote; David C Markel; Weiping Ren; Li Zeng
Journal:  Cartilage       Date:  2016-02-17       Impact factor: 4.634

9.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 10.  Absorption and distribution of xenobiotics.

Authors:  F G Standaert
Journal:  Environ Health Perspect       Date:  1988-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.